Editorial Comment on adjuvant radiotherapy study.
Editorial Comment on adjuvant radiotherapy study.
复制标题
对辅助放射治疗研究的编辑评论。
DOI：
10.1016/j.urology.2008.06.056
复制
发表时间：
2008
期刊：
影响因子：
2.1
通讯作者：
Thompson,IanM
中科院分区：
文献类型：
--
作者：
Thompson,IanM
当被要求写这篇社论时，我最初表示反对。理由：手头的主题是两项随机对照研究的主题，近1500名受试者;两者都报告了初步结果。EORTC试验是一项约1,000名男性的研究，报告了短期结果：放射治疗显著降低了PSA复发。1 SWOG 8794，随访时间更长，显示生化失败的减少更大，将中位失败时间延迟7年。2然而，我们研究的主要终点--无转移生存率--降低了25%，但没有统计学意义（p= 0.06）。我们最近在2008年AUA会议上报告了更新的数据。这篇社论的重点是什么？SWOG和EORTC试验是根据数百例病例系列和关于该主题的综述而开发的。有些是亲辐射，有些是亲观察，PSA后，治疗后，无论是在PSA复发或症状。临床医生可以根据他们阅读或选择引用的病例系列找到对这两种方法的支持。
When asked to write this editorial, I initially demurred. Reasoning: the subject at hand is the subject of two randomized controlled studies of almost 1500 subjects; both have reported initial results. The EORTC trial, a study of about 1,000 men has reported short-term results: a significant reduction in PSA relapse with radiation. 1 SWOG 8794, with longer followup showed an even greater reduction in biochemical failure, delaying median time to failure by 7 years. 2 However, the primary endpoint for our study–metastasis-free survival–was reduced by 25%, but just missed statistical significance (p= 0.06). We recently reported updated data at the 2008 AUA meeting. 3What’s the point of this editorial? The SWOG and EORTC trials were developed in response to hundreds of case series and reviews on this subject. Some are pro-radiation and some are pro-observation, following PSA, and treating later–either at PSA relapse or for symptoms. Clinicians can find support for either approach, based on which case series they read or opt to cite.
影响因子：
158.5
作者：
FISHER, B;BAUER, M;RUSSELL, I
通讯作者：
RUSSELL, I